Rxivist logo

Maternal tamoxifen treatment expands the macrophage population of early mouse embryos.

By RocĂ­o Rojo, Kristin A Sauter, Lucas Lefevre, David A. Hume, Clare Pridans

Posted 06 Apr 2018
bioRxiv DOI: 10.1101/296749

Several different transgenic tamoxifen-inducible cre reporter lines have been used to analyse the contribution of embryonic precursors to the development of the mononuclear phagocyte system in mice. Here we show that tamoxifen treatment of the mother at 8.5dpc with doses commonly-used in lineage trace studies produces a 4-5-fold expansion of the embryonic leukocyte populations by 10.5dpc, detected in whole mounts of embryos using a Csf1r reporter gene or separately by expression of Csf1r, Itgam (CD11b), Adgre1 (F4/80) or Ptprc (CD45) mRNA. These findings indicate that tamoxifen cannot be considered a neutral agonist in macrophage lineage trace studies.

Download data

  • Downloaded 452 times
  • Download rankings, all-time:
    • Site-wide: 36,842 out of 92,758
    • In immunology: 949 out of 2,744
  • Year to date:
    • Site-wide: 36,761 out of 92,758
  • Since beginning of last month:
    • Site-wide: 26,213 out of 92,758

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)